Targeting CD123 in AML: The Latest Therapeutic Advancements
Host: Jennifer Caudle, DO Guest: Naval Daver, MD Not only is CD123 one of the most common antigens expressed on the surface of acute myeloid leukemia (AML) tumors, but it’s also associated with more proliferative disease that’s resistant to standard therapies. Given its prevalenc ...Show more
Navigating a Positive MCED Test and Negative Diagnostic Workup: Real-World Data
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Eric Klein, MD With an urgent need to screen for cancer, clinical trials have shown that the multi-cancer early detection (MCED) test Galleri® can screen for more than 50 distinct cancer types in adults 50 and over and predict its o ...Show more